



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Anti-CD19 [BU12] Bulk Size Ab00823-10.3-BT

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors. Developed in partnership with Ximbio (www.ximbio.com).

This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Isotype and Format: Human IgG1, Fc Silent™, Kappa

Clone Number: BU12

Alternative Name(s) of Target: Leu12; CD19 Molecule; B-Lymphocyte Surface Antigen B4; T-Cell Surface Antigen Leu-12; Differentiation Antigen CD19; CD19 Antigen; CVID3; B4

UniProt Accession Number of Target Protein: P15391

Published Application(s): IP, Therapeutic (block), FC, IHC

Published Species Reactivity: Human

Immunogen: The anti-CD19 antibody-producing hybridoma clone BU-12 was produced by the immunisation of two BALB/c mice with the Burkitt's lymphoma cell line EB4. Immune spleen cells from these animals were fused with the mouse X63 AG8 653 plasmacytoma cell line and resulting hybridomas selected in HAT medium. Screening of hybridoma culture supernatants on a range of T-, B-, myeloid and erythroid cell lines and on sections of normal human tonsil led to the selection of the pan-B-cell-reactive BU-12 hybridoma clone.

Specificity: BU12 reacts specifically with CD19.

Application Notes: BU12 has been found to inhibit specific antibody responses by tonsillar mononuclear cells to influenza virus, and IgG secretion by B lymphoblastoid cell line stimulated with IL-6 (Callard 1992). BU12 has also been used in FACS and radio-iodinated antibody binding studies to determine the levels of CD19 expression on the surface of Ramos and NALM-6 cells (Flavell 2006).

Antibody First Published in: DJ Flavell et al. Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours British Journal of Cancer (1995) 72, 1373-1379
[PMID:8519647](https://pubmed.ncbi.nlm.nih.gov/8519647/)

Note on publication: Describes the construction of immunotoxin BU12-SAPORIN, and its use for selective cytotoxicity of CD19+ target cells in vitro and in vivo.

Product Form

Size: 1 mg Purified antibody in bulk size.

Purification: Protein A affinity purified

Supplied In: PBS only.

Storage Recommendation: Store at 4°C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommended this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.